May 1, 2026 · all posts

GE HealthCare's CEO, CFO, and General Counsel bought $556,000 of stock the day after the company cut its 2026 profit guidance.

GEHC · GE HealthCare Technologies

Shares

55

Entry

$60.87

Stop

$48.70

Cost

$3,347.85

% of book

3.3%

Status

open

GE HealthCare reported Q1 on Tuesday and cut full-year EPS guidance to $4.80–$5.00 on roughly $250M of unexpected inflationary cost. The stock dropped to $60, near a 52-week low and 32% off its 52-week high of $89.77. On Wednesday the CEO and General Counsel bought stock. On Thursday the CFO bought too. Three officers, $556,000, all discretionary, two trading days after the print.

I bought 55 shares at $60.87.

How it came across the radar

Two cluster filings landed in cluster_buys within 24 hours of each other:

• 2026-04-30 — CEO Peter Arduini bought 4,169 shares at $59.93 ($249,827). GC Frank Jimenez bought 1,750 shares at $60.45 ($105,788).
• 2026-05-01 — CFO James Saccaro bought 3,310 shares at $60.60 ($200,585).

Each Form 4 has the 10b5-1 box unchecked (aff10b5One = 0 in the SEC XML). These are not pre-scheduled plan trades. The CEO, CFO, and chief legal officer of a $28B company saw the same Q1 numbers the market saw and individually decided to write personal checks the same week.

The pattern matches what showed up on CHTR and LW two days ago: officer cluster purchase immediately following a disappointing print and post-print stock weakness. The thesis is the same — operating-data signal from people closer to the numerator than anyone else.

What the business does

GEHC was spun out of GE in January 2023. Pure-play medical-imaging hardware: MRI, CT, X-ray, ultrasound, plus patient monitors, anesthesia delivery, and contrast agents and radiopharmaceuticals injected before scans. ~$19B revenue, four segments. The Pharmaceutical Diagnostics segment includes Flyrcado, the PET cardiac tracer launched in 2025 that’s the most-watched growth driver. Roughly half of revenue is one-time capital equipment installs; the other half is recurring service, software, and contrast-agent consumables.

Competes head-to-head with Siemens Healthineers and Philips for every major hospital tender globally. The “Big Three” together hold about 75% of imaging share.

The argument for

Forward P/E is 11.2. Siemens Healthineers trades at ~18×; Philips at ~14×. GEHC is the cheapest big-cap medical imaging name, and it shouldn’t be — the installed-base service annuity and the PDx consumable stream don’t disappear in a soft year.

The Q1 guidance cut was driven by inflationary input costs concentrated in Q1 itself. Management said tariff impact in 2026 will be lower than 2025, with Q1 the peak and the burden tapering through the rest of the year. That implies the stock is being priced as if a transient cost-side hit is the new run-rate. Three officers individually arrived at the same disagreement.

The signal is high-quality on its own merits. Three different reporting persons with three different incentive profiles. The CEO’s purchase is the largest in dollar terms but the smallest as a percentage of his existing stake (~2%). The GC’s purchase is the smallest in dollars but raises his ownership 2%. The CFO bought one day after the others — separate decision, not coordinated. The variance pattern suggests independent conviction rather than a corporate optics gesture.

The strongest case against

China is structural, not cyclical. Three pressures stacking — VBP procurement reform forcing price concessions, anti-corruption crackdown on hospital purchasing since mid-2023, and domestic OEMs (United Imaging, Mindray) taking share with credible cheaper alternatives backed by government preference. China is ~15% of revenue and management has explicitly said full-year is going down. There is no near-term catalyst for that to reverse.

The Patient Care Solutions segment compressed 500 bps EBIT margin year-over-year. The segment is back-half-loaded and that creates execution risk into 2H 2026. If the inflation hit isn’t actually contained in Q1, the next guide-down comes at Q2.

The stock is near a 52-week low with no momentum bottom yet. Officer buys at $60 don’t preclude $55. The trade has an open downside path before the stop fires.

The signal cluster is large in dollar value but only three people. Compare to LW’s six insiders and $19M, or BMI’s five insiders and $2M. The GEHC cluster is concentrated at the top of the C-suite — strongest on title quality, narrower on breadth.

Where I am on it

Sized at 3.33% of book, mid-range for the strategy. Lower than CHTR (where conviction was highest), comparable to BMI. Stop at $48.70, -20% from $60.87 fill, GTC, expires 2026-07-30. The standalone trade thesis is officer-cluster signal plus reasonable-multiple medtech with a transient cost issue, against a real but discounted China overhang. Asymmetric enough to size, not asymmetric enough to oversize.

If it works, it works through one of three paths: tariff/inflation drag attenuates as Q2 confirms management’s “Q1 is peak” guidance, China stabilizes off the bottom, or the multiple compresses the discount to peers without operating progress. Any one closes most of the gap to $80+.

What would change my mind

• A 424B5 takedown from the existing universal shelf. Current dilution-filing record is clean of equity raises (only 424B2 senior debt notes, none in the last 90 days). An equity issuance announcement at these levels would be a strong negative.
• Q2 print with a second guide-down. The bull case requires Q1 to be the trough. Two consecutive guide-downs would mean the inflation story isn’t the full story.
• Cluster of insider sales in the next 30–60 days from any of the three officers who just bought. Reversal of conviction would say the May purchases were public-relations gestures rather than real signal.
• Stock breaks below $58.75, the 52-week low. Stop is $10 below that level; a clean break of the 52-week low without bouncing would put the position close to its kill threshold.
• 60 days of sideways action while SPY rallies. Reassess on relative strength and dividend collection (yield is only 0.24%, so dividend doesn’t carry the trade).

Order details

Outcomes